← all works
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Cancer Immunotherapy and Biomarkers
- Field
- Medicine
- Canadian institutions
- McGill UniversityJewish General Hospital
- Funders
- —
- Keywords
- MedicinePembrolizumabInternal medicineResponse Evaluation Criteria in Solid TumorsOncologyCohortMesotheliomaBiomarkerClinical endpointProspective cohort studyCancerProgressive diseaseDiseaseImmunotherapyPathologyClinical trial
- Has abstract in OpenAlex
- no